Interstitial fibrosis in the heart: differences in extracellular matrix proteins and matrix metalloproteinases in end-stage dilated, ischaemic and valvular cardiomyopathy

被引:51
|
作者
Herpel, E
Pritsch, M
Koch, A
Dengler, TJ
Schirmacher, P
Schnabel, PA
机构
[1] Heidelberg Univ, Dept Pathol, D-69120 Heidelberg, Germany
[2] Heidelberg Univ, Dept Med Biometry, D-69120 Heidelberg, Germany
[3] Heidelberg Univ, Dept Cardiac Surg, D-69120 Heidelberg, Germany
[4] Heidelberg Univ, Dept Internal Med, D-69120 Heidelberg, Germany
关键词
dilated cardiomyopathy; extracellular matrix; remodelling; ischaemic cardiomyopathy; valvular cardiomyopathy;
D O I
10.1111/j.1365-2559.2006.02398.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Aims: To investigate whether or not there are differences in the distribution of extracellular matrix (ECM) proteins and matrix metalloproteinases (MMPs) in end-stage heart failure underlying different cardiomyopathies. Methods and results: Thirty-nine explanted human hearts were investigated: 15 with dilated cardiomyopathy (DCM), 17 with ischaemic cardiomyopathy (ICM) and seven with valvular cardiomyopathy (VCM). Transmural samples from four different sites were investigated. Frozen sections were processed for immunohistochemistry for collagens type I, III, IV, laminin and fibronectin, as well as MMP-1, -2 and -9. Volume densities were determined. All ECM components were expressed more frequently in DCM than in ICM. Comparing ICM with VCM, all proteins were found more frequently in VCM than in ICM except for type III collagen, which was significantly more frequent in ICM. Comparing DCM and VCM, VCM showed significantly higher volume densities for type III collagen and laminin. MMPs showed only slight variations between the cardiomyopathies. Conclusion: The distribution of ECM proteins differs between DCM, ICM and VCM, which suggests that they can be morphologically discriminated by interstitial fibrosis, especially by their expression of matrix proteins.
引用
收藏
页码:736 / 747
页数:12
相关论文
共 50 条
  • [31] Less invasive ventricular enhancement (LIVE) as potential therapy for ischaemic cardiomyopathy end-stage heart failure
    Loforte, Antonio
    Alfonsi, Jacopo
    Gliozzi, Gregorio
    Folesani, Gianluca
    Fiorentino, Mariafrancesca
    Biffi, Mauro
    Marinelli, Giuseppe
    Di Bartolomeo, Roberto
    Pacini, Davide
    JOURNAL OF THORACIC DISEASE, 2019, 11 : S921 - S928
  • [32] EXTRACELLULAR-MATRIX (ECM) PROTEINS AND CELL-ADHESION MOLECULES IN IDIOPATHIC DILATED CARDIOMYOPATHY (IDC)
    GRIMM, D
    ELSNER, D
    HORNER, J
    RUSCHOFF, J
    RIEGGER, GAJ
    KROMER, EP
    CIRCULATION, 1994, 90 (04) : 319 - 319
  • [33] Clinical trial of growth factor therapy for patients with end-stage dilated cardiomyopathy on heart transplantation list
    Komamura, K
    Hanatani, A
    Yamagishi, M
    Mano, A
    Nakatani, T
    Kitamura, S
    Miyatake, K
    Kitakaze, M
    JOURNAL OF CARDIAC FAILURE, 2005, 11 (09) : S264 - S264
  • [34] Familial Dilated Cardiomyopathy (FDCM) Prevalence in End-Stage Non-Ischemic Heart Failure (ESHF)
    Jacoby, D. L.
    DePasquale, E. C.
    Lour, O.
    Pomianowski, P.
    McKenna, W. J.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2012, 31 (04): : S52 - S52
  • [35] Challenges of Palliative Treatment for End-Stage Heart Failure "From a Report of Severe Heart Failure Due to Dilated Cardiomyopathy"
    Oishi, Shogo
    Toba, Takayoshi
    Miyoshi, Naoki
    Takaya, Tomofumi
    Tsukishiro, Yasue
    Yamada, Shinichiro
    Taniguchi, Yasuyo
    Hayashi, Takatoshi
    Yokoyama, Mitsuhiro
    JOURNAL OF CARDIAC FAILURE, 2011, 17 (09) : S177 - S177
  • [36] Right ventricular expression of extracellular matrix proteins, matrix-metalloproteinases, and their inhibitors over a period of 3 years after heart transplantation
    D. J. Schupp
    B. P. Huck
    J. Sykora
    C. Flechtenmacher
    M. Gorenflo
    A. Koch
    F.-U. Sack
    M. Haass
    H. A. Katus
    H. E. Ulmer
    S. Hagl
    H. F. Otto
    P. A. Schnabel
    Virchows Archiv, 2006, 448 : 184 - 194
  • [37] Right ventricular expression of extracellular matrix proteins, matrix-metalloproteinases, and their inhibitors over a period of 3 years after heart transplantation
    Schupp, DJ
    Huck, BP
    Sykora, J
    Flechtenmacher, C
    Gorenflo, M
    Koch, A
    Sack, FU
    Haass, M
    Katus, HA
    Ulmer, HE
    Hagl, S
    Otto, HF
    Schnabel, PA
    VIRCHOWS ARCHIV, 2006, 448 (02) : 184 - 194
  • [38] Regulation of the extracellular matrix proteins in human cardiac fibroblasts derived from endomyocardial biopsies of patients with dilated cardiomyopathy
    Lindner, D.
    Westermann, D.
    Zietsch, C.
    Schultheiss, H-P.
    Tschoepe, C.
    CARDIOVASCULAR RESEARCH, 2010, 87 : S120 - S120
  • [39] Reverse left ventricular remodeling by dobutamine and amiodarone in end-stage heart failure due to idiopathic dilated cardiomyopathy
    Maroulidis, G
    Alexopoulos, G
    Ntalianis, A
    Drakos, S
    Venetsanakos, J
    Christodoulou, K
    Kopelia, M
    Sarafoglou, S
    Savvari, V
    Anastasiou-Nana, M
    JOURNAL OF CARDIAC FAILURE, 2005, 11 (06) : S158 - S158
  • [40] Non-transplant cardiac surgery for end-stage sarcoidosis-induced dilated cardiomyopathy: a bridge for heart transplantation
    Hirota, Masanori
    Hoshino, Joji
    Fukada, Yasuhisa
    Katahira, Shintaro
    Gyoten, Takayuki
    Nohtomi, Yuichi
    Yamasaki, Akira
    Isomura, Tadashi
    CIRCULATION, 2012, 125 (19) : E696 - E696